Insulet
PODD
#1020
Rank
HK$173.11 B
Marketcap
HK$2,459
Share price
2.72%
Change (1 day)
17.36%
Change (1 year)
Categories
Insulet Corporation is an American company that develops and sells medical devices used for the administration of insulin.

P/E ratio for Insulet (PODD)

P/E ratio as of December 2025 (TTM): 90.3

According to Insulet's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 90.2629. At the end of 2024 the company had a P/E ratio of 43.7.

P/E ratio history for Insulet from 2007 to 2025

PE ratio at the end of each year

Year P/E ratio Change
202443.7-40.64%
202373.6-98.25%
2022> 1000263.54%
2021> 1000-50.22%
2020> 1000144.34%
2019951-28.06%
2018> 1000-981.33%
2017-150103.03%
2016-73.9152.07%
2015-29.3-40.82%
2014-49.510.8%
2013-44.7127.5%
2012-19.628.34%
2011-15.3

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
ICU Medical
ICUI
-459-608.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Tandem Diabetes Care
TNDM
-6.79-107.52%๐Ÿ‡บ๐Ÿ‡ธ USA
DexCom
DXCM
35.3-60.92%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
19.4-78.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Abbott Laboratories
ABT
15.6-82.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Medtronic
MDT
28.1-68.87%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
Eli Lilly
LLY
49.4-45.22%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.